A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

The introduction of nivolumab has changed the landscape of relapsed/refractory classical Hodgkin lymphoma (r/r cHL) treatment. Despite its clinical importance, this therapy may remain inaccessible for a significant number of patients worldwide, especially in low-income countries, due to its high cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Lepik, Kirill V., Fedorova, Liudmila V., Kondakova, Elena V., Zalyalov, Yuri R., Babenko, Elena V., Lepik, Elena E., Kotselyabina, Polina V., Beynarovich, Anastasia V., Popova, Marina O., Volkov, Nikita P., Stelmakh, Lilia V., Baykov, Vadim V., Moiseev, Ivan S., Mikhailova, Natalia B., Kulagin, Alexander D., Afanasyev, Boris V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523758/
https://www.ncbi.nlm.nih.gov/pubmed/33062947
http://dx.doi.org/10.1097/HS9.0000000000000480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523758/
https://www.ncbi.nlm.nih.gov/pubmed/33062947
http://dx.doi.org/10.1097/HS9.0000000000000480

Ejemplares similares